Nanotechnology in the Treatment of Inflammatory Bowel Disease

被引:25
|
作者
Giron, Fanny [1 ]
Pasto, Anna [2 ]
Tasciotti, Ennio [3 ,4 ]
Abraham, Bincy P. [3 ,4 ]
机构
[1] Univ Catolica Honduras, San Pedro Sula, Honduras
[2] Ist Oncol Veneto IRCCS, Padua, Italy
[3] Houston Methodist Hosp, Underwood Ctr Digest Disorders, Houston, TX 77030 USA
[4] Houston Methodist Hosp, Houston Methodist Res Inst, Houston, TX 77030 USA
关键词
inflammatory bowel disease; nanoparticles; leukosomes; drug delivery; treatment; PH-SENSITIVE NANOPARTICLES; VASOACTIVE-INTESTINAL-PEPTIDE; IMMUNE-REGULATING CELLS; COLON-SPECIFIC DELIVERY; TNBS-INDUCED COLITIS; DRUG-DELIVERY; IN-VIVO; 5-AMINOSALICYLIC ACID; ULCERATIVE-COLITIS; TRIPEPTIDE KPV;
D O I
10.1093/ibd/izz205
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Due to the lack of cure for inflammatory bowel disease (IBD) and failure of current medical therapies in many patients with IBD, a need exists in finding novel ways to treat inflammation with a high benefit and the lowest risk possible. With current medical therapies, adverse events or risks of cancer/lymphoma and infections prevent patients-and sometimes providers-in using effective therapies for treatment. Some patients develop systemic side effects that preclude them from continuing a therapy that may have been efficacious, or in other cases, current medical therapies are not adequate to control disease. Nanotechnology is an emerging field where particles, in the size of nanometers, can be used to deliver medications directly to the area of inflammation thus avoiding drug-associated systemic side effects. When using nanoparticles (NPs), only a small amount of the drug is needed, and it can be delivered directly to the inflamed site without exposure to the rest of the body. Here we review conventional and unconventional therapies applied in the treatment of IBD underlying how the introduction of NPs has improved their safety and efficacy.
引用
收藏
页码:1871 / 1880
页数:10
相关论文
共 50 条
  • [41] Probiotics in the Treatment of Inflammatory Bowel Disease
    Guandalini, Stefano
    Sansotta, Naire
    PROBIOTICS AND CHILD GASTROINTESTINAL HEALTH: ADVANCES IN MICROBIOLOGY, INFECTIOUS DISEASES AND PUBLIC HEALTH, VOL 10, 2019, 1125 : 101 - 107
  • [42] Methotrexate in the treatment of inflammatory bowel disease
    Dziurkowska-Marek, Anna
    Marek, Tomasz
    PRZEGLAD GASTROENTEROLOGICZNY, 2011, 6 (04): : 225 - 233
  • [43] Bromelain treatment of inflammatory bowel disease
    Hale, LP
    Gottfried, MR
    Onken, JE
    GASTROENTEROLOGY, 2004, 126 (04) : A286 - A287
  • [44] Treatment of Fistulizing Inflammatory Bowel Disease
    Schwartz, David A.
    Maltz, Brad E.
    GASTROENTEROLOGY CLINICS OF NORTH AMERICA, 2009, 38 (04) : 595 - +
  • [45] Treatment with budesonide in inflammatory bowel disease
    Behrens, R
    AUTOIMMUNE DISEASES IN PEDIATRIC GASTROENTEROLOGY, 2002, 127 : 150 - 152
  • [46] Adherence to treatment in inflammatory bowel disease
    San Román, AL
    Bermejo, E
    Carrera, E
    Pérez-Abad, M
    Boixeda, D
    REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, 2005, 97 (04) : 249 - 253
  • [47] Surgical treatment of inflammatory bowel disease
    Strong, SA
    CURRENT OPINION IN GASTROENTEROLOGY, 2002, 18 (04) : 441 - 446
  • [48] Guidelines to the treatment of inflammatory bowel disease
    Bartnik, Witold
    PRZEGLAD GASTROENTEROLOGICZNY, 2007, 2 (05): : 215 - 229
  • [49] Probiotics for the Treatment of Inflammatory Bowel Disease
    Ganesh R. Veerappan
    John Betteridge
    Patrick E. Young
    Current Gastroenterology Reports, 2012, 14 (4) : 324 - 333
  • [50] Thiopurine Treatment in Inflammatory Bowel Disease
    Sharon J. Gardiner
    Evan J. Begg
    Ashis Sau
    Anthony Marinaki
    Richard B. Gearry
    Murray L. Barclay
    Clinical Pharmacokinetics, 2007, 46 : 803 - 804